Campbell, CA, March 25, 2018 — Dark Horse Consulting (DHC), a leading provider of consulting services for the cell and gene therapy industry, today announced that Anthony Davies, Ph.D., CEO and Founder, and Andrew Steinsapir, Consultant, will be presenting at the CBI Optimization of Cell and Gene Therapy Production conference, which is being held in Washington, DC March 26-27.
Dr. Davies will be chairing the Day 1 session, participating in a panel on Process Robustness, Scalability and COGS, and moderating a panel on Regulatory Considerations. Mr. Steinsapir will be presenting a case study on product comparability and technology transfer entitled “Apples, Oranges & Product Comparability.
The full conference agenda can be found at:
About Dark Horse Consulting
Dark Horse Consulting (DHC) specializes in providing strategic and operational support for the Cell and Gene Therapy industry. All of our consultants have deep Cell and Gene Therapy industry experience, spanning diverse functions such as process development, device development, manufacturing, quality, regulatory, program management, business development, strategy, and financing/investor relations. Many of our consultants also bring experiences from adjacent more mature sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, we deeply understand the unique challenges faced by Cell and Gene Therapy developers and are able to apply best practices from other industries to address the needs of our clients.
Our team of Cell and Gene Therapy professionals brings deep technical expertise to help you tackle the unique challenges of our exciting young field.